Answers are grounded in this paper and cite their sources.
Participants in research trials often disclose severe depression symptoms, including thoughts of self-harm and suicidal ideation, in validated self-administered questionnaires such as the Patient Health Questionnaire (PHQ-9). However, there is no standard protocol for responding to such disclosure, and the opportunity to support people at risk is potentially missed. We developed and evaluated a risk assessment protocol for the IBD-BOOST randomised controlled trial (ISRCTN71618461 09/09/2019).
No takes yet. Share an insight, caveat, or question.
Wileman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: